Table 3

Absolute and relative values of oral medication, injectable medication and metformin-based combination therapies in the treatment of type 2 diabetes mellitus in the Diabetes Registry Tyrol by age groups

Class18–39 years, n (%)40–59 years, n (%)60–79 years, n (%)80–99 years, n (%)
Oral medication
 Oral antidiabetic drugs108 (58.4)1672 (75.1)4297 (70.6)1331 (56.1)
 Metformin or gliptins101 (54.6)1541 (69.2)3859 (63.4)1034 (43.6)
 Metformin100 (54.1)1446 (65.0)3347 (55.0)690 (29.1)
 Gliptins21 (11.4)590 (26.5)1852 (30.5)604 (25.4)
 SGLT-2i22 (11.9)437 (19.6)753 (12.4)58 (2.4)
 Sulfonylurea analogs7 (3.8)136 (6.1)528 (8.7)323 (13.6)
 Glitazones4 (2.2)116 (5.2)239 (3.9)40 (1.7)
 Glucosidase inhibitors0 (0)4 (0.2)21 (0.4)14 (0.6)
Injectable medication
 Insulin or analogs56 (30.3)754 (33.9)2623 (43.1)1267 (53.4)
 Insulin analogs42 (22.7)578 (26.0)2092 (34.4)933 (39.3)
 Insulin40 (21.6)498 (22.4)1822 (30.0)818 (34.5)
 GLP-1a8 (4.3)109 (4.9)174 (2.9)10 (0.4)
Metformin-based combinations
 Metformin and gliptins20 (10.8)490 (22.0)1343 (22.1)262 (11.0)
 Metformin and (insulin/analogs)27 (14.6)426 (19.1)1153 (19.0)252 (10.6)
 Metformin and SGLT-2i19 (10.3)372 (16.7)619 (10.2)39 (1.6)
 Metformin and sulfonylurea5 (2.7)87 (3.9)320 (5.3)91 (3.8)
 Metformin and SGLT-2i and gliptin4 (2.2)154 (6.9)283 (4.7)18 (0.8)
 Metformin and glitazone3 (1.6)89 (4.0)168 (2.8)21 (0.9)
 Metformin and GLP-1a8 (4.3)79 (3.6)117 (1.9)6 (0.3)
 Metformin and SGLT-2i and GLP-1a5 (2.70)27 (1.2)41 (0.7)2 (0.1)
 Total185 (100)2227 (100)6083 (100)2374 (100)
  • GLP-1a, glucagon-like peptide-1 agonist; SGLT-2i, sodium/glucose cotransporter 2 inhibitor.